[{"orgOrder":0,"company":"Sprout Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Flibanserin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sprout Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sprout Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sprout Pharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Flibanserin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

OPRD USA
Not Confirmed
OPRD USA
Not Confirmed

Details : The baseline means Female Sexual Function Index (FSFI) score was 13.3, with FSFI- desire score of 1.96 after 8 weeks on Addyi (flibanserin), an FDA-approved non-hormonal pill mean FSFI total score increased to 19.4, and the mean FSFI-d score increased to...

Product Name : Addyi

Product Type : Small molecule

Upfront Cash : Not Applicable

March 15, 2022

Lead Product(s) : Flibanserin

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank